Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Tackling The High Rejection Rate For Invented Names In The EU

Executive Summary

Despite a revamp of the EU guideline on choosing a brand name for a new drug, more names continue to be rejected than accepted. The Pink Sheet’s Ian Schofield spoke to Alexios Skarlatos, the chair of the Name Review Group at the European Medicines Agency, and Jose Ferrero, a scientific administrator at the agency, to find out why and what can be done to improve things. It’s a lot more complex than you might think.

Related Content

Topics

UsernamePublicRestriction

Register

PS121042

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel